TAINAN, Taiwan, July 30 /PRNewswire/ --

Eli Lilly Company (Lilly) and ScinoPharm Taiwan Ltd. (ScinoPharm) announced today that they have reached an amicable resolution of all ongoing patent litigations between the companies relating to ScinoPharm's manufacture and sale of gemcitabine hydrochloride around the world.

As part of the settlement, Lilly has granted ScinoPharm a royalty bearing license to manufacture and sell gemcitabine hydrochloride (API) throughout the world, excluding only countries where the Lilly compound or method of use patents remain in force and the United States.

About ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd. is a leading process RD and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. Combining cost-effective resources and productivity of Asia along with extensive regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical RD and manufacturing needs at any level and for any company in this sector. For more information please visit http://www.scinopharm.com .

About Eli Lilly Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com .

Media Contact: ScinoPharm Taiwan, Ltd. Jessie Wang Tel: +886-6-505-2888 Email: Jessie.wang@scinopharm.com.tw

SOURCE: ScinoPharm Taiwan, Ltd.

Jessie Wang of ScinoPharm Taiwan, Ltd., +886-6-505-2888, Jessie.wang@scinopharm.com.tw